Emergency study to test the safety of Descartes-30 cells in patients with moderate-to-severe acute respiratory distress syndrome (ARDS) AND COVID-19
Biological: Descartes 30
Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases.
Inclusion Criteria:
- Patients must be 18 years of age or older at the time of enrollment
- Patient maintains a diagnosis of moderate or severe ARDS according to the Berlin
definition of ARDS
Exclusion Criteria:
- Patient is currently enrolled into another therapeutic clinical trial with an
experimental therapy that has not received marketing approval by U.S. FDA.
- Patient is in moribund state with expected survival <24 hours.
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
University of Maryland Medical Center Medical Center
Baltimore, Maryland, United States
Hafsa Kamboh, MD
3013488698
trials@cartesiantx.com